In a message sent to employees this week, global CDMO Catalent announced that it would be letting go up to 400 employees at its Bloomington, Indiana site.
The letter sent to workers, shared by local news outlet the Bloomingtonian, said that the company would be informing employees between November 30 and December 2nd. Catalent’s Vice President and general manager Andrew Espejo sent the organizational announcement, citing “a challenging global economic environment, which requires the company to manage its cost for the post-pandemic world.” The workforce reduction will primarily affect the operations team, Espejo said.
It’s been a few busy years for Catalent, who played a leading role in COVID vaccine productions. As demand for these jabs has dropped, the CDMO has announced structural changes and cost-reduction measures including more than 200 layoffs in its Texas and Maryland facilities.
Back in July, Catalent revealed changes to its operating structure and executive leadership team that reflected "evolving customer and industry trends and position the company to deliver its next level of growth and achievement,” the CDMO’s new CEO Alessandro Maselli said at the time. Catalent’s new structure consolidated the company's four reporting segments into two — one focused on biologics and the other on pharmaceuticals and consumer health.
